首页 | 本学科首页   官方微博 | 高级检索  
     


VKORC1 and CYP2C9 genotypes are predictors of warfarin‐related outcomes in children
Authors:Kaitlyn Shaw MSc  Ursula Amstutz PhD  Claudette Hildebrand RN  S. Rod Rassekh MD  MHSc  Martin Hosking MD  Kathleen Neville MD  MSc  J. Steven Leeder PharmD  PhD  Michael R. Hayden MD  PhD   FRCPC  Colin J. Ross MSc  PhD  Bruce C. Carleton PharmD
Affiliation:1. Department of Pediatrics, Faculty of Medicine, University of British Columbia (UBC), , Vancouver, BC, Canada;2. Pharmaceutical Outcomes Programme, B.C. Children's Hospital, , Vancouver, BC, Canada;3. Division of Pediatric Hematology/Oncology/BMT, B.C. Children's Hospital, , Vancouver, BC, Canada;4. Division of Pediatric Cardiology, B.C. Children's Hospital, , Vancouver, BC, Canada;5. Division of Pediatric Hematology/Oncology, Children's Mercy Hospitals and Clinics, , Kansas City, Missouri;6. Division of Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, , Kansas City, Missouri;7. Centre for Molecular Medicine and Therapeutics, UBC, , Vancouver, BC, Canada
Abstract:
Keywords:anticoagulant  children  CYP2C9  pharmacogenetics  VKORC1  warfarin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号